Washington: A new study has revealed that single dose of the neuraminidase inhibitor (NAI) peramivir has shown promising results in treating influenza symptoms, including fever and viral shedding.
An analysis of phase 2 and phase 3 clinical trials showed that a single injected dose appeared to be safe and effective at alleviating influenza symptoms, when administered within 48 hours of the onset of symptoms.
Rich Whitley of the University of Alabama at Birmingham said that based on clinical data, peramivir would be the first neuraminidase inhibitor (NAI) that has shown to be safe and effective as a single-dose therapy for patients with acute, uncomplicated influenza.
Peramivir has been approved in Japan and Korea since 2010, and it is estimated that 1 million Japanese patients have received drug post-approval. To date, more than 2,700 subjects have been treated with peramivir in 27 clinical trials. If approved by the FDA, peramivir would be the only single-dose and injection treatment for influenza in the U.S., and would be the first new NAI approved in more than a decade.